Assessing Response of Guadecitabine Treatment along with the correlation between number of cycles with response and survival in Acute Myeloid Leukemia patients
Latest Information Update: 04 Dec 2019
Price :
$35 *
At a glance
- Drugs Guadecitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2019 New trial record
- 06 Nov 2019 Results (N=206), assessing the correlation between an HMA number of cycles with response and survival in Acute Myeloid Leukemia patients treated with Guadecitabine, released at the 61st Annual Meeting and Exposition of the American Society of Hematology